製品の概要

  • 製品名
    Sorafenib
  • 製品の詳細
    Potent multikinase inhibitor
  • 別名
    • BAY 43-9006
    • Nexavar
  • 生理活性の詳細

    Potent multikinase inhibitor that targets the RAF/MEK/ERK pathway in tumor cells, and tyrosine kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Inhibits Raf-1, B-Raf, VEGFR-2, VEGFR-3, PDGFR-β, Flt3, c-KIT and FGFR-1 (IC50 values are 6 nM, 22 nM, 90 nM, 20 nM, 57 nM, 58 nM, 68 nM and 580 nM in cell-free assays, respectively).

  • 精製度
    > 98%

製品の特性

  • 体系名
    4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
  • 分子量
    464.82
  • 構造式
    Chemical Structure
  • 分子式
    C21H16ClF3N4O3
  • CAS 番号
    284461-73-0
  • PubChem 登録番号
    216239
  • 保存方法
    Shipped at Room Temperature. Store at -20°C. Store under desiccating conditions.
  • 溶解性
    Soluble in DMSO to 100 mM
  • 使用に関する注意

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES 線形表記
    CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
  • 由来

    Synthetic

参考文献

This product has been referenced in:
  • Davoudi ET  et al. Sorafenib in renal cell carcinoma. Pak J Pharm Sci 27:203-8 (2014). Read more (PubMed: 24374450) »
  • Liu L  et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-8 (2006). Read more (PubMed: 17178882) »
  • Adnane L  et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407:597-612 (2006). Read more (PubMed: 16757355) »
  • Wilhelm SM  et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-109 (2004). Read more (PubMed: 15466206) »

See 0 Publications for this product

レビューと Q&A

There are currently no Customer reviews or Questions for ab141966.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

登録